Roche ramps up immunotherapy R&D
Swiss cancer meds world market leader Roche intensifies its focus on translational research to broaden the scope of cancer immunotherapies.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2151 entries already.
Entries by Thomas Gabrielczyk
Roche ramps up immunotherapy R&D
Swiss cancer meds world market leader Roche intensifies its focus on translational research to broaden the scope of cancer immunotherapies.
Roche ramps up immunotherapy R&D
Swiss cancer meds world market leader Roche intensifies its focus on translational research to broaden the scope of cancer immunotherapies.
Roche ramps up immunotherapy R&D
Swiss cancer meds world market leader Roche intensifies its focus on translational research to broaden the scope of cancer immunotherapies.
Roche ramps up immunotherapy R&D
Swiss cancer meds world market leader Roche intensifies its focus on translational research to broaden the scope of cancer immunotherapies.
Adaptimmune downgrades trial design after FDA clinical hold
Oxford-based immuno-oncology play Adaptimmune has been obliged by the FDA to alter the trial design of a Phase I/II study in patients with MRCLS. A partial clinical hold was lifted now.
Multiple sclerosis diagnosis in early stage
Belgian and German researchers have presented a new imaging tool that can track immune cells invading the brain in the initial stages of multiple sclerosis (MS).
BIO Europe with new record numbers
Despite declining numbers of IPOs, financing rounds and licensing deals, the European biotech sector presented itself optimistic and self-confident during BIO-Europe in Cologne. The three-days partnering event again see a record number of participants.
AZ withdraws lung cancer drug from EU lead market
After AstraZeneca removed its NSCLC drug osimertinib from the German market following a benefit assessment of German health technology assessor G-BA negatively impacting price negotiations, the German oncologist association DGHO accuses the G-BA not to act in the best interest of lung cancer patients.
Bioregions deliver action plan blueprint
While DG Research has delayed its update on the European Bioeconomy Strategy and Action Plan until next June, the Central and Eastern Bioregions presented a blueprint that proposes key actions aimed at integrating the goals of the European Commission’s circular economy and the bioeconomy strategies.